日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Lethal clinical outcome and chemotherapy and immunotherapy resistance in patients with urothelial carcinoma with MDM2 amplification or overexpression

MDM2扩增或过表达的尿路上皮癌患者出现致命的临床结局以及化疗和免疫治疗耐药性

期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2024-010964
Jin, Kaifeng; Ding, Yawei; Xu, Jingtong; Liu, Zhaopei; Zeng, Han; Su, Xiaohe; Zhang, Lingkai; Sun, Jiaxing; Wu, Yuzhen; Liu, Hailong; Chang, Yuan; Zhu, Yu; Wang, Zewei; Xu, Le; Zhang, Weijuan; Xu, Jiejie
肿瘤
肿瘤免疫
MDM2
治疗耐药
免疫/内分泌
发表日期：2025
文献求助 收藏

ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma.

ARID1A 缺失加上 CD8+ T 细胞浸润与尿路上皮癌的良好临床结果相关。

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-25-0816
Liu Zhaopei, Zhang Lingkai, Jin Kaifeng, Zeng Han, Su Xiaohe, Ding Yawei, Sun Jiaxing, Wu Yuzhen, Liu Hailong, Zhu Yu, Xu Le, Zhang Weijuan, Wang Zewei, Chang Yuan, Xu Jiejie
细胞生物学
T细胞
CD8
ID1
发表日期：2025
文献求助 收藏

COVID-19 and acute limb ischemia: latest hypotheses of pathophysiology and molecular mechanisms

COVID-19 与急性肢体缺血：病理生理学和分子机制的最新假说

期刊:Journal of Zhejiang University-Science B
影响因子:4.9
doi:10.1631/jzus.B2300512
Yao, Chengjun; Dong, Yanzhao; Zhou, Haiying; Zou, Xiaodi; Alhaskawi, Ahmad; Ezzi, Sohaib Hasan Abdullah; Wang, Zewei; Lai, Jingtian; Kota, Vishnu Goutham; Abdulla, Mohamed Hasan Abdulla Hasan; Liu, Zhenfeng; Abdalbary, Sahar Ahmed; Alenikova, Olga; Lu, Hui
发表日期：2025
文献求助 收藏

Nicotinamide Riboside Mitigates Retinal Degeneration by Suppressing Damaged DNA-Stimulated Microglial Activation and STING-Mediated Pyroptosis.

烟酰胺核苷通过抑制受损 DNA 刺激的小胶质细胞活化和 STING 介导的细胞焦亡来减轻视网膜变性

期刊:Investigative Ophthalmology & Visual Science
影响因子:4.7
doi:10.1167/iovs.66.4.14
Zhu Shanshan, Zhang Lusi, Tong Ping, Chen Jiawei, Wang Cong, Wang Zewei, Liu Jingyuan, Duan Peiyun, Jiang Qian, Zhou Yubing, Tan Guangshuang, Zhang Xian, Jiang Bing
细胞生物学
焦亡
发表日期：2025
文献求助 收藏

IVC treatment between primary and second TURBT may improve the prognosis of high-risk NMIBC patients receiving BCG treatment

在初次和二次经尿道膀胱肿瘤切除术（TURBT）之间进行下腔静脉（IVC）治疗可能改善接受卡介苗（BCG）治疗的高危非肌层浸润性膀胱癌（NMIBC）患者的预后。

期刊:Scientific Reports
影响因子:3.9
doi:10.1038/s41598-025-89008-x
Li, Zhen; Wang, Zewei; Liu, Yang; Yang, Lei; Gu, Ling; Li, Hailong; Wang, Wei
膀胱癌
肿瘤免疫
肿瘤
发表日期：2025
文献求助 收藏

Publisher Correction: IVC treatment between primary and second TURBT may improve the prognosis of high-risk NMIBC patients receiving BCG treatment

出版商更正：在初次和二次经尿道膀胱肿瘤切除术（TURBT）之间进行下腔静脉（IVC）治疗可能改善接受卡介苗（BCG）治疗的高危非肌层浸润性膀胱癌（NMIBC）患者的预后。

期刊:Scientific Reports
影响因子:3.9
doi:10.1038/s41598-025-98177-8
Li, Zhen; Wang, Zewei; Liu, Yang; Yang, Lei; Gu, Ling; Li, Hailong; Wang, Wei
膀胱癌
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Intravesical chemotherapy in BCG waiting period may prolong time to recurrence for high-risk NMIBC patients

在 BCG 等待期间进行膀胱内化疗可能延长高危 NMIBC 患者的复发时间

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-025-13705-z
Li, Zhen; Wang, Zewei; Wu, Jiyue; Zhang, Feilong; Gan, Lijian; Wang, Wei; Li, Hailong; Gu, Ling
发表日期：2025
文献求助 收藏

Clinicopathological and molecular correlates of clinical benefit from disitamab vedotin (RC48), a HER-2-targeting antibody-drug conjugate, in metastatic urothelial carcinoma: a multi-center, real-world study

转移性尿路上皮癌中靶向HER-2的抗体药物偶联物disitamab vedotin (RC48) 的临床获益的临床病理学和分子相关性：一项多中心真实世界研究

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-025-14870-x
Liu, Zhaopei; Jin, Kaifeng; Xu, Ziyue; Zeng, Han; Su, Xiaohe; Xu, Jingtong; Ding, Yawei; Liu, Hailong; Zhu, Yu; Xu, Le; Xu, Jiejie; Wang, Zewei; Chang, Yuan
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

The cAMP-PKA signaling pathway induces apoptosis and promotes hypothermic liver injury

cAMP-PKA信号通路诱导细胞凋亡并促进低温性肝损伤。

期刊:World Journal of Emergency Medicine
影响因子:3.2
doi:10.5847/wjem.j.1920-8642.2025.114
Liu, Ying; Cheng, Feng; Wang, Zewei; Juan, Du; Yuan, Zhixin; Tian, Xiaoye; Ma, Ruihang; Jin, Hongxu
凋亡
表观遗传
PKA
信号转导
肝损伤
GPCR/Calcium/cAMP
细胞生物学
毒理研究
发表日期：2025
文献求助 收藏

Visceral Adipose Predicts Prognosis and Toxicities in Locally Advanced Bladder Cancer Patients Treated With Adjuvant Gemcitabine Plus Cisplatin Chemotherapy

内脏脂肪可预测接受吉西他滨联合顺铂辅助化疗的局部晚期膀胱癌患者的预后和毒性反应

期刊:Cancer Medicine
影响因子:3.1
doi:10.1002/cam4.70742
Gao, Zhimin; Zhang, Lei; Li, Zhen; Qin, Xu; Wang, Zewei; Wang, Junqi; Qi, Nienie; Li, Hailong
肿瘤
毒理研究
肿瘤免疫
膀胱癌
发表日期：2025
文献求助 收藏